ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial
ProMIS Neurosciences Inc. announced its financial results for the third quarter ended September 30, 2025. The company reported research and development expenses of $9.8 million for the quarter, an increase from $2.6 million in the same period of 2024, primarily due to expenditures on the PRECISE-AD Phase 1b clinical trial for its lead candidate, PMN310. General and administrative expenses were $2.0 million, compared to $1.9 million in the prior year quarter. The loss from operations was $11.8 million, up from $4.4 million in the third quarter of 2024. ProMIS also provided a clinical update, stating that its Phase 1b trial in Alzheimer's disease is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 nearing completion. PMN310 continues to demonstrate a favorable safety profile. The company remains on track to report 6-month interim data in the second quarter of 2026 and final 12-month top-line results in the fourth quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-109714), on November 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.